A Large Ion Collider Experiment (ALICE) is an experiment station at CERN that detects quark-gluon plasma, a state of matter thought to have formed immediately after the big bang. A plan was proposed ...to upgrade the particle detector in the Inner Tracking System (ITS) of ALICE by 2020. In the upgrade, new silicon sensor technology, the Monolithic Active Pixel Sensor (MAPS), will be used to replace the ITS. The new sensor is called ALICE PIxel DEtector (ALPIDE). This project focused on the characterization of ALPIDE sensors with a new version of a pixel sensor telescope using the 1.2 GeV electron beam at the Synchrotron Light Research Institute Beam Test Facility (SLRI-BTF). Seven ALPIDE sensors were lined up as a stacked sensor to perform a test using the electron beam at SLRI-BTF. The previous version of the telescope could only characterize the middle area of the sensor; however, the new sensor telescope can be used to characterize edges and corners of the sensor. This advantage provides us with a complete view of the detection efficiency in all sections of the ALPIDE sensor. The detection efficiency of the sensor will be investigated and analyzed by EUTelescope software.
Oxytocin is used for initiating uterine contraction and preventing postpartum hemorrhage during caesarean delivery. Using a lower dosage of oxytocin may lower the risk of adverse effects while still ...being effective in stimulating initial uterine contraction. We aimed to compare the effectiveness and side effects of the standard 10 IU bolus of oxytocin with those of a 5 IU bolus during caesarean delivery.
We enrolled women in a randomized, double-blind, study comparing intravenous injections of high-dose (10 IU) and low-dose (5 IU) oxytocin administered after clamping of the umbilical cord. The primary outcome was adequate uterine contraction within the first 3 mins after administration. Secondary outcomes included uterine tone, use of additional uterotonic agents, additional obstetrics procedures, and oxytocin-related adverse events.
A total of 155 women underwent randomization, with 78 in the low-dose group and 77 in the high-dose group. The proportion of women with adequate uterine contraction during the first 3 mins was 84.6% in the low-dose group and 77.9% in the high-dose group (relative risk, 1.09; 95% CI, 0.93 to 1.26). Methylergonovine maleate was used in 14.1% of cases in the low-dose group and 36.4% in the high-dose group (relative risk, 0.40; 95% CI, 0.22 to 0.73). The necessity for additional obstetric procedures, estimated blood loss >500 mL, neonatal outcomes, and oxytocin-related adverse effects did not differ significantly between the two groups.
The 5 IU bolus of oxytocin was noninferior to the standard 10 IU bolus of oxytocin for initiating adequate uterine contraction, required fewer additional uterotonic agents, and led to fewer oxytocin-related adverse events.
PDF
